PhytoMedical Plans to Expand Compound Pipeline
PRINCETON, New Jersey -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today unveiled plans to expand its pipeline of development compounds, following recent news announcing favorable research outcomes and accelerated development of the Company's 'polyphenol' class of compounds for type-2 diabetes.
In a January 16, 2007 press release, PhytoMedical announced that the Company is finalizing the developmental transition of its new class of polyphenolic compounds -- which possess unique antioxidant and insulin enhancing qualities, distinct from existing classes of drugs for diabetes -- to a highly respected, pre-clinical centric laboratory. This will enable PhytoMedical to expedite the pursuit of an Investigational New Drug (IND) application with the FDA which, if approved, allows the Company to initiate Phase 1 human studies.
"Our lead compound for type-2 diabetes is continuing to move along the development pathway based on positive research findings in the lab. The timing is right for us to now further expand our portfolio compounds addressing clinical targets that are being actively sought-after by big pharma," explained Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc.
"With large industry players in the market eagerly seeking proven compounds in development, and with our compound for type-2 diabetes showing encouraging results, PhytoMedical is well positioned to pursue additional, promising early-stage pharmaceutical opportunities and focus our attention in the areas of cancer, Alzheimer's, cardiovascular, diabetes, obesity, cholesterol, and other high-demand targets," Mr. Wujek concluded.
In a published study of type-2 diabetes patients, PhytoMedical's polyphenolic compounds significantly reduced blood sugar levels by an average of 18 to 29 percent, triglycerides (fatty acids in blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent, and total cholesterol by 12 to 26 percent. Amazingly, no side effects were reported in the study.
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit www.phytomedical.com
Contacts
PhytoMedical Technologies, Inc.
Shareholder Communications
Ms. Sharon Gershony, 800-611-3388
www.phytomedical.com
In a January 16, 2007 press release, PhytoMedical announced that the Company is finalizing the developmental transition of its new class of polyphenolic compounds -- which possess unique antioxidant and insulin enhancing qualities, distinct from existing classes of drugs for diabetes -- to a highly respected, pre-clinical centric laboratory. This will enable PhytoMedical to expedite the pursuit of an Investigational New Drug (IND) application with the FDA which, if approved, allows the Company to initiate Phase 1 human studies.
"Our lead compound for type-2 diabetes is continuing to move along the development pathway based on positive research findings in the lab. The timing is right for us to now further expand our portfolio compounds addressing clinical targets that are being actively sought-after by big pharma," explained Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc.
"With large industry players in the market eagerly seeking proven compounds in development, and with our compound for type-2 diabetes showing encouraging results, PhytoMedical is well positioned to pursue additional, promising early-stage pharmaceutical opportunities and focus our attention in the areas of cancer, Alzheimer's, cardiovascular, diabetes, obesity, cholesterol, and other high-demand targets," Mr. Wujek concluded.
In a published study of type-2 diabetes patients, PhytoMedical's polyphenolic compounds significantly reduced blood sugar levels by an average of 18 to 29 percent, triglycerides (fatty acids in blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent, and total cholesterol by 12 to 26 percent. Amazingly, no side effects were reported in the study.
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit www.phytomedical.com
Contacts
PhytoMedical Technologies, Inc.
Shareholder Communications
Ms. Sharon Gershony, 800-611-3388
www.phytomedical.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.